TMCnet News
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe
Mensia
Technologies, french MedTech start up, leads the new booming
category of Digital therapeutics with its revolutionary « at home «
neurofeedback, to train the brain and cure neuropsy disorders without
drugs.
Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in
Rennes are computing real time signaling softwares. The neurofeedback
technique is non invasive, at home and without drugs. MENSIA
KOALA treats ADHD, Attention Deficit Disorders with or without
Hyperactivity, children and adolescents. This unique medical device is a
therapeutic video game on an interactive tablet connected to the brain
activity. Children learn to control their attention by exercising 3
times a week during 4 months of treatment. Visual feedback given during
the game, allows the children to learn, control and create automatisms.
Six years of R&D with 12 $millions invested, including the last largest
clinical multicentric trial never ver made, NEWROFEED-Koala,
successfuly lead to the grant of a CE mark class IIa in Europe. Kick
start of the sales in March for France. Michel du Peloux, CEO of Mensia Technologies : « We are proud to deliver the first worldwide digital therapeutic device to treat ADHD with a Class IIa registration for medical scripts and follow up all over Europe. Far from neurogaming, we have 5 patents, randomised clinical trials and state of the art expertise in brain computer interface. Our pipeline of « at home neurofeedback » is promising : resistant chronic low back pain despite opiods, is our next medical device. Mensia Technologies initiates now the next tour for a serie A of 20 M$ aiming to the USA deployement.
About Mensia Technologies : https://www.mensia.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005925/en/ |